Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

NCT04847232 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2690

Enrollment

INDUSTRY

Sponsor class

Stopped The event rate observed in the study continued to be below primary assumptions, so that the completion of the study within a reasonable timeframe was deemed very unlikely.

Conditions

Hyperkalemia

Interventions

DRUG: Sodium Zirconium Cyclosilicate (SZC)
DRUG: SZC Placebo

Sponsor

AstraZeneca